Skip to content
Screener

Upstream Bio, Inc. UPB Free cash flow

Free cash flow at other companies

Amgen logo
AmgenAMGN
$3.49B+82.6%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$572.8M-38.1%
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
-$19.91M-98.8%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
-$10.26M+1.6%
Savara logo
SavaraSVRA
-$29.97M-14.1%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$25.94M-142%

Other financials

Income statement

See full
Revenue$773.0K-17.5%
Operating income-$42.4M+4.5%
Net income-$39.7M+0.7%
EPS (diluted)-$0.73+1.4%

Balance sheet

See full
Cash & equivalents$79.4M+74.7%
Total debt$954.0K-38.9%
Total equity$271.0M-33.7%
Total assets$281.2M-33.1%

Cash flow

See full
Operating cash flow-$35.6M+9.2%
CapEx$54.0K-70.8%

Valuation

See full
Market cap$394.54M-54.7%
Enterprise value$316.1M-61.6%
P/S124.9×-195×

Profitability

See full
Operating margin-5,382.6%+1,393pp
Net margin-4,955.7%+2,041pp

Returns & leverage

See full
Return on equity-46%
Debt / equity0.0×
Current ratio28×-10.3×

Where this comes from

Calculated from Upstream Bio, Inc.’s reported figures.

The source filing: Upstream Bio, Inc.’s 10-K, filed March 26, 2026. Open the filing →

Filed
Mar 26, 2026, 4:04 PM EDT
Fiscal year
FY2025
Accession
0001193125-26-126188

FAQ

What is Upstream Bio, Inc.'s free cash flow?
Upstream Bio, Inc. (UPB) reported free cash flow of -$30.69M in Q4 2025.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.

Ask your AI about Upstream Bio, Inc.'s free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude